Patents by Inventor Kay Schreiter

Kay Schreiter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions
    Patent number: 8853193
    Abstract: The present invention relates to novel thienopyrimidine compounds of general formula pharmaceutical compositions comprising these compounds and their therapeutic use for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: October 7, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Armin Heckel, Frank Himmelsbach, Joerg Kley, Thorsten Lehmann-Lintz, Norbert Redemann, Achim Sauer, Leo Thomas, Dieter Wiedenmayer, Phillip Black, Wesley Blackaby, Ian Linney, Matthias Austen, John Danilewicz, Martin Schneider, Kay Schreiter
  • Cycloalkyl containing thienopyrimidines for pharmaceutical compositions
    Patent number: 8754079
    Abstract: The present invention relates to novel thienopyrimidine compounds of general formula pharmaceutical compositions comprising these compounds and their therapeutic use for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: June 17, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thorsten Lehmann-Lintz, Armin Heckel, Joerg Kley, Elke Langkopf, Norbert Redemann, Achim Sauer, Leo Thomas, Dieter Wiedenmayer, Matthias Austen, John Danilewicz, Martin Schneider, Kay Schreiter, Phillip Black, Wesley Blackaby, Ian Linney
  • Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions
    Patent number: 8648068
    Abstract: The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: February 11, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thorsten Lehmann-Lintz, Joerg Kley, Norbert Redemann, Achim Sauer, Leo Thomas, Dieter Wiedenmayer, Matthias Austen, John Danilewicz, Martin Schneider, Kay Schreiter, Phillip Black, Wesley Blackaby, Ian Linney
  • Thienopyrimidines for pharmaceutical compositions
    Patent number: 8486953
    Abstract: The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
    Type: Grant
    Filed: August 24, 2009
    Date of Patent: July 16, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Austen, Phillip Black, Wesley Blackaby, John Danilewicz, Ian Linney, Kay Schreiter, Martin Schneider
  • HALOGEN OR CYANO SUBSTITUTED THIENO [2,3-D]PYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS
    Publication number: 20130065914
    Abstract: The present invention relates to novel thienopyhmidine compounds of general formula (I), pharmaceutical compositions comprising these compounds and their therapeutic use for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
    Type: Application
    Filed: February 25, 2011
    Publication date: March 14, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Armin Heckel, Frank Himmelsbach, Thorsten Lehmann-Lintz, Norbert Redemann, Achim Sauer, Leo Thomas, Phillip Black, Wesley Blackaby, John Danilewicz, Ian Linney, Matthias Austen, Martin Schneider, Kay Schreiter
  • THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS
    Publication number: 20120128686
    Abstract: The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
    Type: Application
    Filed: August 24, 2009
    Publication date: May 24, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Matthias Austen, Phillip Black, Wesley Blackaby, John Danilewicz, Ian Linney, Kay Schreiter, Martin Schneider
  • Crystallographic structure of Mnk-1 and Mnk-2 proteins
    Patent number: 8129164
    Abstract: The present invention relates to crystalline Mnk-1 and Mnk-2 kinases and, in particular, to the crystal structure of Mnk-1 and Mnk-2 kinase domain.
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: March 6, 2012
    Assignees: Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V., Boehringer Ingelheim International GmbH
    Inventors: Markus Wahl, Ralf Jauch, Kay Schreiter, Stefan Jakel
  • CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS
    Publication number: 20110217311
    Abstract: The present invention relates to novel thienopyrimidine compounds of general formula pharmaceutical compositions comprising these compounds and their therapeutic use for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
    Type: Application
    Filed: February 25, 2011
    Publication date: September 8, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Thorsten LEHMANN-LINTZ, Armin HECKEL, Joerg KLEY, Elke LANGKOPF, Nobert REDEMANN, Achim SAUER, Leo THOMAS, Dieter WIEDENMAYER, Matthias AUSTEN, John DANILEWICZ, Martin SCHNEIDER, Kay SCHREITER, Phillip BLACK, Wesley BLACKABY, Ian LINNEY
  • HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS
    Publication number: 20110212102
    Abstract: The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
    Type: Application
    Filed: February 25, 2011
    Publication date: September 1, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Thorsten LEHMANN-LINTZ, Joerg KLEY, Norbert REDEMANN, Achim SAUER, Leo THOMAS, Dieter WIEDENMAYER, Matthias AUSTEN, John DANILEWICZ, Martin SCHNEIDER, Kay SCHREITER, Phillip BLACK, Wesley BLACKABY, Ian LINNEY
  • THIENOPYRIMIDINES CONTAINING A SUBSTITUTED ALKYL GROUP FOR PHARMACEUTICAL COMPOSITIONS
    Publication number: 20110212103
    Abstract: The present invention relates to novel thienopyrimidine compounds of general formula pharmaceutical compositions comprising these compounds and their therapeutic use for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
    Type: Application
    Filed: February 25, 2011
    Publication date: September 1, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Armin HECKEL, Frank HIMMELSBACH, Joerg KLEY, Thorsten LEHMANN-LINTZ, Norbert REDEMANN, Achim SAUER, Leo THOMAS, Dieter WIEDENMAYER, Phillip BLACK, Wesley BLACKABY, Ian LINNEY, Matthias AUSTEN, John DANILEWICZ, Martin SCHNEIDER, Kay SCHREITER
  • Crystallographic Structure of Mnk-1 and Mnk-2 Proteins
    Publication number: 20110159568
    Abstract: The present invention relates to crystalline Mnk-1 and Mnk-2 kinases and, in particular, to the crystal structure of Mnk-1 and Mnk-2 kinase domain.
    Type: Application
    Filed: February 8, 2011
    Publication date: June 30, 2011
    Inventors: Markus Wahl, Ralf Jauch, Kay Schreiter, Stefan Jäkel
  • Crystallographic structure of Mnk-1 and Mnk-2 proteins
    Patent number: 7943357
    Abstract: The present invention relates to crystalline Mnk-1 and Mnk-2 kinases and, in particular, to the crystal structure of Mnk-1 and Mnk-2 kinase domain.
    Type: Grant
    Filed: March 8, 2006
    Date of Patent: May 17, 2011
    Assignees: Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V., Boehringer Ingelheim International GmbH
    Inventors: Markus Wahl, Ralf Jauch, Kay Schreiter, Stefan Jäkel
  • Lipin1 function
    Publication number: 20050260709
    Abstract: The present invention addresses the mechanistic role of Lipin1 in the absence of embryonic development. Accordingly, the present invention relates to novel Lipin1 polypeptides and nucleic acids encoding these polypeptides, which polypeptides are involved in body-weight regulation, energy homeostasis, metabolism, obesity, and diabetes. Furthermore, the invention provides substances modulating the function of the polypeptides of the invention, in particular siRNAs inhibiting Lipin1 function in general and Lipin1B2 function in particular and the medical uses of Lipin1 activators and inhibitors.
    Type: Application
    Filed: March 4, 2005
    Publication date: November 24, 2005
    Inventors: Uwe Andag, Kay Schreiter